Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment

In this study, utilizing mouse models of PDAC, we showed that inhibition of either HGF/c-Met or Hh pathways sensitize the PDAC tumors to gemcitabine, resulting in decreased primary tumor volume as well as significant reduction of metastatic tumor burden. However, prolonged treatment of single HGF/c-Met or Hh inhibitor leads to resistance to these single inhibitors, likely because the single c-Met treatment leads to enhanced expression of Shh, and vice versa. Targeting both the HGF/c-Met and Hh pathways simultaneously overcame the resistance to the single-inhibitor treatment and led to a more potent antitumor effect in combination with the chemotherapy treatment. Mol Cancer Ther; 16(11); 2399–409. ©2017 AACR.

Source: Molecular Cancer Therapeutics - November 1, 2017 Category: Cancer & Oncology Authors: Rucki, A. A., Xiao, Q., Muth, S., Chen, J., Che, X., Kleponis, J., Sharma, R., Anders, R. A., Jaffee, E. M., Zheng, L. Tags: Small Molecule Therapeutics Source Type: research